Consideration of Nebulized Lidocaine For Treatment of Covid19 Severity Via Targeting Neutrophil Extracellular Traps

Abstract

Coronavirus disease 2019 (Covid19) is a viral-provoked respiratory disease that affects many patients worldwide. Clinical manifestations start with mild flu-like symptoms and progress to acute respiratory distress syndrome (ARDS), the trigger of which has been underpinned as cytokine storm. Neutrophil-derived neutrophil extracellular traps (NETs) greatly contribute to development of Covid19 severity. It has been hypothesized that nebulized lidocaine could be used to attenuate the severity of Covid19, however, the mechanism by which this may occur not completely clear. This review addresses the possibility of using nebulized lidocaine as a therapeutic approach for targeting Covid19-induced NETs formation.